Shares of Takeda Pharmaceutical Co Ltd (NYSE:TAK) have been given an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy recommendation.
Brokerages have set a twelve-month consensus target price of $23.80 for the company, according to Zacks. Zacks has also given Takeda Pharmaceutical an industry rank of 90 out of 256 based on the ratings given to its competitors.
A number of research analysts recently weighed in on TAK shares. Zacks Investment Research upgraded shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research report on Wednesday, July 17th. ValuEngine downgraded shares of Takeda Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Wednesday, May 15th.
Shares of NYSE:TAK traded up $0.55 during trading on Tuesday, reaching $17.92. 1,766,994 shares of the stock traded hands, compared to its average volume of 2,922,482. The firm’s 50-day moving average price is $17.56. Takeda Pharmaceutical has a 52-week low of $15.50 and a 52-week high of $21.95. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.01 and a current ratio of 1.46. The company has a market capitalization of $28.03 billion, a PE ratio of 35.14 and a beta of 0.69.
Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings data on Tuesday, May 14th. The company reported $0.13 earnings per share for the quarter. The company had revenue of $3.51 billion for the quarter. Takeda Pharmaceutical had a net margin of 4.01% and a return on equity of 11.23%. Analysts predict that Takeda Pharmaceutical will post 0.41 earnings per share for the current year.
A number of institutional investors have recently modified their holdings of TAK. Shelton Capital Management bought a new position in Takeda Pharmaceutical in the first quarter worth approximately $46,000. Hudock Capital Group LLC purchased a new position in Takeda Pharmaceutical during the first quarter valued at $26,000. Shine Investment Advisory Services Inc. purchased a new position in Takeda Pharmaceutical during the first quarter valued at $28,000. Contravisory Investment Management Inc. purchased a new position in Takeda Pharmaceutical during the first quarter valued at $28,000. Finally, Parallel Advisors LLC purchased a new position in Takeda Pharmaceutical during the first quarter valued at $33,000. Institutional investors own 11.42% of the company’s stock.
About Takeda Pharmaceutical
Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.
Recommended Story: Cash Flow
Get a free copy of the Zacks research report on Takeda Pharmaceutical (TAK)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.